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Background: Phase-shift nanoemulsions (PSNEs) provide cavitation sites when the perfluorocarbon (PFC)
nanodroplets (ND) are vaporized to microbubbles by acoustic energy. Their presence lowers the power required to
ablate tissue by high-intensity focused ultrasound (HIFU), potentially making it a safer option for a broader range of
treatment sites. However, spatial control over the ablation region can be problematic when cavitation is used to
enhance heating. This study explored relationships between vaporization, ablation, and the PSNE concentration
in vitro to optimize the acoustic intensity and insonation time required for spatially controlled ablation
enhancement using a PSNE that included a volatile PFC component.
Methods: HIFU (continuous wave at 1 MHz; insonation times of 5, 10, 15, and 20 s; cool-down times of 2, 4,
and 6 s; peak negative pressures of 2, 3, and 4 MPa) was applied to albumin-acrylamide gels containing PFC agents
(1:1 mix of volatile decafluorobutane and more stable dodecafluoropentane at 105 to 108 PFC ND per milliliter) or
agent-free controls. Vaporization fields (microbubble clouds) were imaged by conventional ultrasound, and ablation
lesions were measured directly by calipers. Controlled ablation was defined as the production of ‘cigar’-shaped
lesions corresponding with the acoustic focal zone. This control was considered to be lost when ablation occurred
in prefocal vaporization fields having a predominantly ‘tadpole’ or oblong shape.
Results: Changes in the vaporization field shape and location occurred on a continuum with increasing PSNE
concentration and acoustic intensity. Working with the maximum concentration-intensity combinations resulting in
controlled ablation demonstrated a dose-responsive relationship between insonation time and volumes of both the
vaporization fields (approximately 20 to 240 mm3) and the ablation lesions (1 to 135 mm3) within them.
Conclusions: HIFU ablation was enhanced by this PSNE and could be achieved using intensities ≤650 W/cm2.
Although the ablation lesions were located within much larger microbubble clouds, optimum insonation times
and intensities could be selected to achieve an ablation lesion of desired size and location for a given PSNE
concentration. This demonstration of controllable enhancement using a PSNE that contained a volatile PFC
component is another step toward developing phase-shift nanotechnology as a potential clinical tool to
improve HIFU.
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High-intensity focused ultrasound (HIFU) is approved
by the FDA in the USA for the treatment of uterine fi-
broids and is being evaluated for treating other kinds of
tumors [1]. Ultrasound can kill cells by thermal effects
(heating and denaturing proteins) and mechanical effects
(disrupting cellular membranes). Both effects are en-
hanced if appropriately sized bubbles are present in the
acoustic field [2,3]. Bubbles in an acoustic field oscillate
(stable cavitation), absorbing ultrasound energy and re-
leasing it as heat, and collapse (inertial cavitation), produ-
cing local shock waves [2]. Ultrasound can draw bubbles
from the dissolved gases in biologic tissue. However, the
required pressures [4] can result in the formation of bub-
ble clusters or clouds with an unpredictable density and
therefore an unpredictable enhancement of lesion forma-
tion. Hence, currently available HIFU systems employ
acoustic parameters chosen to limit bubble formation.
Without the assistance of cavitation, high intensities in the
range of 2,000 W/cm2 are needed to reach ablative tem-
peratures [5,6]. These intensities place healthy tissue in
the ultrasound path at risk [7]. In order to avoid unwanted
thermal damage, HIFU is delivered in short bursts sepa-
rated by cool-down periods. The transrectal application of
HIFU for prostate cancer employs 3 to 5 s of therapeutic
insonation (‘on’ time), during which ablation occurs,
followed by 5 to 6 s of cool-down (‘off ’ time) [5,6]. Since
each therapeutic burst results in an ablation lesion meas-
uring 30 to 40 mm3, 2 to 5 h is typically required to ablate
the total volume of prostate cancer. During this time, local
or generalized anesthesia and tissue cooling are required.
In response to these limitations, research is underway to
minimize the energy required by HIFU to achieve tumor
ablation. Enhanced focused ultrasound seeks to take ad-
vantage of cavitation, rather than avoid it, by seeding the
acoustic field with bubbles.
Many studies to date have confirmed the ability of
micron-sized bubbles or ‘microbubbles’, including com-
mercially available ultrasound contrast agents, to enhance
HIFU in experimental models [3,8-12]. Enhancement re-
fers to the faster production of larger ablation lesions using
lower delivered energy. Ultrasound contrast agents are typ-
ically composed of high molecular weight gases, including
volatile perfluorocarbons (PFC) such as octafluoropropane
(C3F8, b.p. = −37°C), encapsulated in protein, polymer, or
lipid shells [13]. These agents are designed to improve
diagnostic imaging, and as such, they have short half-lives
in vivo and are confined to the vasculature by their size
[14]. Since they cannot penetrate into diseased tissue or
remain in circulation for the time required to deliver
therapeutic ultrasound, microbubbles have limited dir-
ect clinical utility in the setting of HIFU.
As a potential solution, PFC microbubbles can be gen-
erated in tissues by vaporizing liquid PFC nanodroplets(ND) using energy delivered by ultrasound [15]. Since
the PFC core is encapsulated by surfactant, these parti-
cles are often referred to collectively as phase-shift
nanoemulsions (PSNEs). PSNEs remain stable for hours
at body temperature in solution and in vivo [16,17].
Additionally, droplets can be small enough (<300 nm) to
extravasate through the leaky vasculature in malignant
and inflamed tissues and have been shown to accumu-
late in tumors following their intravenous administration
[17]. Therefore, PSNEs hold promise as potentially use-
ful agents to enhance HIFU [15,18], and their behavior
in response to HIFU has been studied in solution [16],
in tissue-mimicking gels [9,19,20], and in animals [17].
However, control over ablation lesion geometry and
placement can be problematic when the acoustic field con-
tains PFC microbubbles or PSNEs. In an early trial of
HIFU enhancement using octafluoropropane microbubbles
in a tissue-mimicking gel, undesirable distortion in ablation
lesions was noted with increasing bubble concentrations
[11]. At lower bubble concentrations, the ablation lesions
were ‘cigars’ (prolate ellipsoids, vertical axis > lateral axis)
corresponding with the HIFU focal zone. As bubble
concentrations increased, larger ablation lesions be-
came ‘tadpoles’, describing both their geometric ap-
pearance (asymmetric ellipsoids) and their relocation
or migration away from the focal point and closer to the
ultrasound source. Eventually, the ablation lesions flat-
tened (oblate ellipsoids, lateral axis > vertical axis) along
the frontal gel surface, completely ‘shadowing’ the desired
focal point. The largest ablation lesions were therefore
achieved at a price of lost control over lesion geometry
and location. Similar control problems have also been
encountered during HIFU enhancement with the use
of liquid PFC droplets during phase-shift studies
[9,20,21]. Using dodecafluoropentane (DDFP) droplets
in an albumin-acrylamide gel model, Zhang P. et al.
described ‘teardrop’ ablation lesions at higher inten-
sities (>830 W/cm2) [20], while Zhang M. et al. reported
complete loss of an ablation response at the highest
microdroplet concentration [21]. The authors hypothe-
sized that this loss resulted from ‘backscatter from the
high-density acoustic droplet vaporization bubbles drawn
proximally to shadow the focus’ [21].
Research is therefore being done to manipulate the
HIFU acoustic parameters and PSNE concentrations to
achieve controlled enhancement. The acoustic energy re-
quired to trigger the critical phase-shift from liquid
droplet to microbubble is dependent on temperature,
the frequency of insonation, the size of the droplet, and
the type of PFC compound [15,22]. Smaller droplets are
more difficult to vaporize than larger droplets, and vola-
tile PFCs are easier to vaporize than less-volatile com-
pounds. Most studies using phase-shift emulsions to
enhance HIFU have employed PFC droplets containing
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boiling point close to body temperature [17,19-21]. As
shown in a tissue-mimicking gel model, there is a large
difference between the relatively high (approximately 8
MPa at a frequency of 2 MHz) peak negative pressure
(PNP) required to vaporize DDFP droplets <500 nm in
diameter and the much lower acoustic pressure needed
to drive inertial cavitation once bubbles have been gen-
erated [19]. This difference provides an opportunity to
control the otherwise unpredictable ablation response in
the setting of cavitation. A brief (<1 ms) high-pressure
pulse is used to localize vaporization, followed by con-
tinuous wave insonation at lower pressure to drive cavi-
tation and achieve ablation.
Our laboratory has been exploring the possible diagnos-
tic and therapeutic applications of PSNEs containing highly
volatile PFC compounds, including decafluorobutane
(DFB, C4F10, b.p. = −2°C) [23]. Blending PFC compounds
to tune the vaporization threshold of PSNEs has been
explored since its introduction in 2005 [24]. Previous ex-
periments looking at HIFU enhancement using a PSNE
containing a 1:1 mix of DFB and DDFP demonstrated
vaporization within 10 to 20 ms of continuous wave
HIFU (1 MHz) delivered at a pressure as low as 2 MPa.
This low pressure was also adequate to drive cavitation
and achieve ablation. Given this absence of a large dif-
ference between the pressures required for vaporization
and cavitation, continuous wave HIFU was applied with-
out a vaporization pulse [9]. The results defined the upper
and lower nanodroplet concentration and acoustic pres-
sure limits required to achieve enhanced ablation. Add-
itionally, comparing the behavior of liquid nanodroplets
and microbubbles directly demonstrated that droplet
vaporization could be achieved focally, allowing for con-
trol over the location of ablation, although the ablation
lesions were contained within larger vaporization fields of
microbubbles.
The current study examined the effect of varying the
insonation (‘on’) and cool-down (‘off ’) times of the HIFU
treatment cycle on the resulting microbubble clouds and
ablation lesions within them over a range of PSNE con-
centrations and acoustic pressures. It is now clear that
control over ablation during enhanced HIFU requires
selecting the appropriate acoustic parameters for the
available PFC concentration, a fact that is of particular
importance when working with more volatile PSNEs.
Zhang P. et al. have suggested that ‘there may potentially
be an optimal range of acoustic intensities that allow for
taking advantage of bubble-enhanced heating while
avoiding distortion in lesion shape’ [20]. The goal of this
study was therefore to optimize the acoustic intensity
and insonation time for a given concentration of this
unique PFC agent during continuous wave HIFU. The
demonstration of controllable ablation in the presenceof a volatile PFC component is another step toward de-
veloping PSNEs as useful clinical tools to enhance HIFU.
Methods
Preparation of the phase-shift perfluorocarbon
nanoemulsion
The PSNE was prepared by the condensation proced-
ure described previously [23]. Lipids (1,2-distearoyl-sn-
glycero-3-phosphocholine and 1,2-distearoyl-sn-glyce
ro-3-phosphoethanolamine-N-methoxy(polyethylene-glycol)-
2000, purchased from Avanti Polar Lipids (Alabaster, AL,
USA) in a 9:1 M ratio and a total lipid concentration of
1.0 mg/mL) were emulsified in a solution of propylene
glycol 15% (v/v), glycerol 5% (v/v), and phosphate-
buffered saline 80% (v/v). Then, 1.5 mL of the lipid
mixture was placed in a sealed 3-mL glass vial and the
air headspace exchanged with PFC gas (equal parts
decafluorobutane (C4F10) and dodecafluoropentane (C5F12),
purchased from Fluoromed (Round Rock, TX, USA)).
Microbubbles with PFC cores (1:1 ratio of DFB and DDFP)
and phospholipid shells formed spontaneously during agita-
tion using a Vialmix Shaker (Bristol-Myers-Squibb, New
York, NY, USA). The concentration of microbubbles in this
emulsion was measured in triplicate using an Accusizer
780 (Particle Sizing Systems, Santa Barbara, CA, USA) and
was found to be 1010 microbubbles per milliliter. Conden-
sation of the microbubbles to nanodroplets was achieved
by cooling the emulsion under an adjustable high-pressure
air source in a CO2/isopropanol bath maintained at a
temperature between −5°C and −10°C. The mixture was
swirled gently while the headspace pressure in the vial was
steadily increased until a change in the consistency of the
solution indicated the onset of condensation. The droplets
measured 240 ± 65 nm in diameter as determined by
dynamic light scattering (Malvern Nano ZS, Malvern
Instruments, Ltd., Westborough, MA, USA). Assuming
a 1:1 conversion from microbubble to nanodroplet, a final
PSNE stock solution containing 1010 PFC nanodroplets
per milliliter was stored and used within 24 h.
Tissue-mimicking phantom
Albumin-acrylamide tissue-mimicking phantoms were
prepared and formed into 10-mL frustums (top diameter,
3 cm; bottom diameter, 4.1 cm; height, 1.2 cm) containing
various concentrations of the stock PSNE [9,25]. The
PSNE was gently stirred into the degassed acrylamide
solution prior to polymerization in the frustum mold by
the addition of 1% v/v of 10% ammonium persulfate and
0.4% v/v tetramethylethylenediamine. These albumin-
acrylamide gels have acoustic properties similar to biologic
tissues. Based on the final albumin concentration in these
gels (35%), its density was 995 kg/m3, and sound traveled
within the gel at a speed of 1,543 m/s [25]. In these stud-
ies, HIFU was delivered at 1 MHz, and at this frequency,
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fields (microbubble clouds) within the phantoms can be
imaged by ultrasound (Figure 1A). Furthermore, the ini-
tially transparent gel turns opaque white in regions where
the albumin is denatured at temperatures above 60°C,
allowing for direct visual measurement of the ablation le-
sions (Figure 1B,C).
Gel model of diseased tissue
A model for HIFU delivery was constructed as described
previously in order to simulate a region of diseased tissue
surrounded by healthy tissue [9]. The phantom containing
the PFC nanoemulsion sat in a gellan gum mold [26] and5 mm 
5 mm 
Figure 1 Vaporization field (microbubble cloud) and ablation
lesion images obtained after applying continuous wave HIFU.
HIFU was applied at 1 MHz to albumin-acrylamide gel phantoms
containing 5 × 105 PFC ND per milliliter. (A) This ultrasound image
shows a cigar-shaped vaporization field generated after 20 s of HIFU
at 650 W/cm2 (4 MPa). (B) These optical images show four opaque
white ablation lesions located in each transparent gel phantom
following the application of HIFU at 650 W/cm2 for 5, 10, 15 and
20 s. Larger lesions can be observed in phantoms treated with
longer insonation times. (C) A single ablation lesion cut along its
vertical axis, demonstrating the desired cigar shape.was covered by a 10-mm-thick degassed, agent-free
albumin-acrylamide gel cap. The mold and cap mimicked
the healthy tissue surrounding the diseased phantom.
Since they have similar acoustic impedances (albumin-
acrylamide gel: 1.54 × 106, gellan gum mold: 1.62 × 106
kg/m2s) [25,26], significant reflection should not occur at
the gel and mold interfaces. This in vitro model was
designed to simulate PFC agent accumulation in a tumor.
PSNE accumulation has been demonstrated in vivo [17]
and is believed to result from the enhanced permeability
of tumor vasculature [27]. The layered arrangement of
gels allowed for assessment of ablation along the
HIFU beam path and ensured that acoustic energies
were low enough to avoid ablation in prefocal tissue re-
gions containing no PFC agent. The tissue-mimicking gels
and mold were maintained at a constant body temperature
of 37°C by a bath circulating degassed water.
Focused ultrasound
A spherically focused, eight-element, annular array trans-
ducer with active outer and inner diameters of 80 and
33.5 mm and a natural focal length of 80 mm (F# = 1)
(Imasonic, Voray-sur-l’Ognon, France) was driven using a
Therapy Imaging Probe System (TIPS) (Philips Research
North America, Briarcliff Manor, NY, USA) to provide
continuous wave HIFU at 1 MHz. The transducer was cal-
ibrated at 2, 3, and 4 MPa using a needle hydrophone
(Onda HNA-0400, Sunnyvale, CA, USA) positioned at the
focal point (TIPS focal zone: 1 × 1 × 6 mm) in a degassed
water bath (free-field). Since measuring the acoustic in-
tensity at the focal point directly in gels during HIFU
is challenging, the intensities are estimates based on
calculation using the free-field focal pressure, the
acoustic impedance of the albumin-acrylamide gel, and the
frequency-dependent attenuation by the gel. The nonlinear
pressure waveform amplitudes recorded during calibration
were derated for gel attenuation and averaged to obtain
the focal pressure in the gel, which was squared and di-
vided by the gel acoustic impedance (density × sound
speed) to estimate the spatial peak intensity (ISP) in the
focal zone during HIFU [28]. Intensities corresponding to
PNPs of 2, 3, and 4 MPa were 140, 390, and 650 W/cm2,
respectively. Previous experimentation has shown that (1)
a PNP of 1 MPa (intensity = 30 W/cm2) does not generate
a vaporization field or an ablation lesion across the
nanodroplet concentration range used in this study, (2)
both vaporization and ablation occur at a pressure of 2
MPa, demonstrating no large difference between the
vaporization and cavitation pressure thresholds, and (3)
agent-free (non-enhanced) ablation is just beginning to
occur at a PNP of 4 MPa [9]. Acoustic intensities below
140 and above 650 W/cm2 were therefore not explored
further. The HIFU treatment cycle was varied with
insonation times of 5, 10, 15, and 20 s followed by cool-
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separate ablation lesions were generated in each phantom
(Figure 1B). The same insonation time (5, 10, 15, or 20 s)
was used to create each lesion in a single phantom. The
cool-down time (2, 4, or 6 s) referred to the time separat-
ing each of the four insonations, during which time the
HIFU focus was moved to a new position in the gel. The
four focal zones in each phantom were separated by 8
mm. This separation distance was selected based on the
results of previous testing [9] demonstrating that the di-
ameters of the vaporization fields in the presence of this
specific PSNE approach 8 mm at higher acoustic inten-
sities and ND concentrations. Testing at each acoustic
parameter was carried out at least eight times. The ultra-
sound transducer was positioned over the phantom at the
focal length of 80 mm (64 mm through degassed water, 16
mm through albumin-acrylamide gel) and moved auto-
matically by a programmable 3-D motion stage.
Vaporization field shape and location
Liquid nanodroplets are only very weakly echogenic, since
their density and compressibility are similar to surround-
ing tissue. However, the vaporization field (microbubble
cloud) resulting from their phase-shift can be imaged by
conventional ultrasound with high sensitivity [9]. In order
to determine the maximum PSNE concentration allowable
to produce an ablation lesion with the desired cigar shape
centered at the focal point for a given acoustic intensity,
continuous wave HIFU was applied for 20 s using PNPs of
2, 3, and 4 MPa to phantoms containing 0.1, 0.5, 1.0, 2.5,
10, 50, and 100 μL of the PSNE stock solution. The
resulting nanodroplet concentrations in the phantoms
were not measured directly, but assuming minimal PFC
agent loss during preparation, they were calculated to
be 1 × 105, 5 × 105, 1 × 106, 2.5 ×106, 1 × 107, 5 ×
107, and 1 × 108 ND per milliliter, respectively. Reported
as a volume fraction (v/v) of the PSNE stock solution
added to the 10 mL gel phantom, these concentrations
were equivalent to a range from 0.001% to 1%. This broad
range (105 to 108 ND per milliliter) was studied to docu-
ment the behavior of this novel PSNE and to define the
upper and lower PSNE concentration limits for effective
HIFU enhancement. The lower concentrations are com-
parable to those used in other PFC microdroplet and
nanodroplet phase-shift enhancement studies [20,21] and
are more likely to be achievable in vivo.
The resulting vaporization fields were imaged using a
15 L8 transducer probe with a Siemens Sequoia scanner
(Siemens, Mountain View, CA, USA) operating in B-
mode (frequency = 14 MHz, mechanical index = 0.7). This
imaging did not trigger PFC nanodroplet vaporization as
confirmed by imaging phantoms prior to HIFU treatment.
The microbubble cloud shapes and locations in the gel
phantoms were analyzed using ImageJ software. Theirlateral axis lengths, perimeters, and areas were measured
and used to quantify the changing cloud shape (distor-
tion). The progression from cigar to tadpole to oblate
ellipsoid (Figure 2) can be demonstrated mathematically
by a lengthening of the lateral axis and an increasing area-
to-perimeter ratio. In order to quantify displacement of
the microbubble cloud off the acoustic focus (center shift),
the centroid of the cloud was calculated in ImageJ and its
distance from the acoustic focus (assumed to be on the
central plane of the phantom) was measured. Further test-
ing of microbubble cloud and ablation lesion volumes in
response to varied insonation and cool-down times was
carried out using the maximum PSNE concentration for a
given acoustic intensity that contained predominantly
cigar-shaped ablation lesions centered at the acoustic focal
point.
Vaporization field and ablation lesion volumes
Previous testing has demonstrated that PFC-enhanced
HIFU ablation lesions in the presence of a DFB-DDFP
PSNE are located in larger vaporization fields (microbubble
clouds) [9]. Knowing the extent of the vaporization field
is useful when planning a strategy to position adjacent
ablation lesions. A 15L8 transducer probe with a Siemens
Sequoia scanner operating in B-mode at 14 MHz was used
to image the vaporization field immediately after each
HIFU treatment (Figure 1A). The PSNE concentration-
intensity combinations identified for further study yielded
vaporization fields characterized predominately as cigars
when insonation times were less than 20 s. However, early
tadpole transformation was present for some microbubble
clouds after 20 s of insonation. Given this asymmetry, the
volumes of all microbubble clouds were calculated using
code written in Matlab. The code allowed a region of
interest to be outlined (microbubble cloud perimeter) and
sectioned horizontally. Three-dimensional disc volumes
were calculated from these two-dimensional sections and
the disc volumes summed for a total volume approxima-
tion. Ablation lesions were apparent as opaque white re-
gions in the otherwise transparent phantom (Figure 1B,C).
To determine the volume of these predominantly cigar-
shaped lesions, the phantoms were cut by scalpel through
the central vertical plane of the lesion (Figure 1C). The
maximum height (h) and width (w) of these ablation le-
sions were measured by calipers, and the correspond-
ing prolate ellipsoid volume (V) was calculated: V =
(4/3) × π × (h/2) × (w/2)2.
Statistical analysis
Means and corresponding standard deviations (S.D.) were
reported and represented on the graphs, and p values
of <0.05 (α) were considered to be statistically significant.
One-way analysis of variance (ANOVA) was used to com-
pare the means when more than two sample groups were
5 mm 
A B C
Figure 2 Schematic representation of the changing shape of vaporization fields (microbubble clouds) with increasing PFC
concentrations and acoustic energies. (A) The desired shape is a cigar (prolate ellipsoid) centered at the acoustic focal point (white dot).
(B) Tadpole lesions (asymmetric ellipsoids) occur as vaporization begins to concentrate in prefocal regions. (C) Eventually, the microbubble clouds
flatten (oblate ellipsoids) and mass along the frontal phantom surface. These shape changes (distortion) can be appreciated qualitatively and can
also be assessed quantitatively by measuring the length of the lateral axis (horizontal white line), the area-to-perimeter ratio, and the
displacement of the centroid off of the focal plane (center shift).
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to the accepted level for statistical significance (p = α/N) in
order to compare combinations of sample pairs (N) by
Student's t test within the larger group.
Results
Vaporization field shape and location as a function of
nanodroplet concentration and acoustic intensity
The maximum PFC nanodroplet concentration appropri-
ate for a given HIFU intensity was selected based on the
results of evaluating the vaporization field (microbubble
cloud) shape and location across a broad range of concen-
trations (105 to 108 ND per milliliter) treated by continu-
ous wave HIFU for 20 s at 2, 3, and 4 MPa (intensities
of 140, 390, and 650 W/cm2). Figure 3 shows the
progressive shape and location changes observed with
increasing PSNE concentrations: cigar surrounding the
central acoustic focal point, tadpole with prefocal migra-
tion, and eventually flattened microbubble clouds along
the frontal surface. These changes result from vaporization
concentrating in prefocal areas and are associated with a5 x 105 106 2
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Figure 3 Representative acoustic images of vaporization fields (micro
HIFU. HIFU was applied at 1 MHz for 20 s at intensities of 140, 390, and 65
containing PFC nanodroplets over a concentration range from 105 to 108 N
of the microbubble clouds with increasing PSNE concentrations can be see
(prolate ellipsoid) to tadpole (asymmetric ellipsoid) to oblate ellipsoid, as varisk of ablation occurring away from the intended target
site. Although flattening of the microbubble clouds along
the prefocal phantom surface was an artifact of the layered
gel model, their appearance was nevertheless a clear indi-
cation that control over the placement of the vaporization
field had been lost. The transformations in microbubble
cloud shape (distortion) occurred on a continuum, as
reflected by the logarithmic relationship between the lat-
eral axis lengths and PSNE concentration for a given
acoustic intensity (R2 ≥ 0.94, p < 0.001, linear regression
on log scale) (Figure 4A). This cigar to tadpole transform-
ation was reflected by a statistically significant (p ≤ 0.01)
change in the area-to-perimeter ratio (Figure 4B) with
increasing PSNE concentration. The point of initial
distortion corresponded with a statistically significant
(p ≤ 0.03) center shift (Figure 4C). For the range of
PSNE concentrations and acoustic intensities tested,
distortion and center shift increased with increasing
intensity for a given concentration and also occurred
at lower PSNE concentrations in response to higher
acoustic intensities (Figure 4B,C)..5 x 106 107 5 x 107 108
ration (nanodroplets/mL) 
10 mm 
bubble clouds) generated by the application of continuous wave
0 W/cm2 (PNP = 2, 3, and 4 MPa) to albumin-acrylamide phantoms
D per milliliter. The progressive changes in the shape and location
n. The shape change follows a predictable pattern from cigar
porization concentrates in prefocal regions.
AB
C 
Figure 4 Quantitative assessment of the progressive changes in
the shape and location of the vaporization fields. (A) There is a
logarithmic relationship between the length of the lateral axis and
the PSNE concentration for a given acoustic intensity (R2 ≥ 0.94, p <
0.001, linear regression on log scale), demonstrating that most of the
change occurs in the lower PSNE concentration range. (B) Change
in the area-to-perimeter ratio reflects changes in the microbubble
cloud shape (distortion). (C) Prefocal displacement of the centroid
(center shift) as a function of PSNE concentration. The first PSNE
concentration for a given intensity to demonstrate a statistically
significant increase in distortion compared to the previous
concentration (p ≤ 0.01 by Student's t test) corresponded with the
first concentration to demonstrate a statistically significant center
shift (p ≤ 0.03 by Student's t test). These are the points of early
tadpole transformation and occurred at PSNE concentrations of 5 ×
105, 2.5 × 106, and 1 × 107 ND per milliliter using intensities of 650,
390, and 140 W/cm2 (PNP = 4, 3, and 2 MPa), respectively. (n ≥ 4,
mean ± S.D.). The arrowed bracket identifies this transformation
point for an acoustic intensity of 140 W/cm2.
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tions of 5 × 105, 2.5 × 106, and 1 × 107 ND per milliliter
(0.005%, 0.025%, 0.1% v/v) using intensities of 650,
390, and 140 W/cm2, respectively. These concentration-
intensity combinations were chosen for further study,
since they were the maximum points at which predomin-
ately cigar-shaped ablation lesions could still be found
after 20 s of insonation. Of note, these intensities and
PSNE concentration ranges are similar to those reported
previously [20].
Vaporization field volume as a function of the HIFU
treatment cycle
The treatment cycle of continuous wave HIFU refers to
the insonation (‘on’ or ablation) time and the ‘off ’ or
cool-down time that separates the insonation times. For
a given intensity, there was no statistically significant
difference in the volumes of the vaporization fields
(microbubble clouds) when insonation was separated by
‘off ’ times lasting 2, 4, or 6 s. This consistency was present
across the entire range of insonation times (Figure 5).
Given the fact that varying the separation times did
not affect the vaporization volume, all measurements
collected for a given insonation time were averaged for
further analysis. There was a statistically significant dose-
responsive relationship (ANOVA, p < 0.02) between the
duration of HIFU insonation and the volumes of the
resulting vaporization fields (Figure 6). The volumes of
the vaporization field ranged from approximately 75 to
240 mm3 with the application of HIFU at 650 W/cm2
from 5 to 20 s, respectively, in phantoms containing 5 ×
105 ND per milliliter. These fields were much smaller
when 140 W/cm2 was applied to phantoms containing 1 ×
107 ND per milliliter, ranging from approximately 15
mm3 after 5 s of insonation to 25 mm3 after 20 s. Add-
itionally, at this lowest acoustic intensity, the vaporization
AB
C 
Figure 5 Relationships between the volume of the vaporization
field, separation time, and insonation time. At intensities of
(A) 140, (B) 390, and (C) 650 W/cm2, no statistically significant
differences were observed between the volumes of the vaporization
fields at separation times of 2, 4, and 6 s for any given insonation
time (n ≥ 4, mean ± S.D.).
*
*
Figure 6 Volume of the vaporization field (microbubble cloud)
as a function of the duration of insonation. n ≥12, mean ± S.D.,
p < 0.02 for values along each intensity curve (ANOVA), Single
asterisk (*) indicates significance (p < 0.008) between the volumes of
the vaporization fields at insonation times of 5 and 20 s for the
given acoustic intensity (Bonferroni correction to Student's t test).
Puett et al. Journal of Therapeutic Ultrasound 2013, 1:16 Page 8 of 13
http://www.jtultrasound.com/content/1/1/16response was inconsistent, demonstrating that this is the
minimum intensity required to achieve vaporization using
this PSNE.
Bubble fields were not seen by conventional acoustic
imaging in the agent-free phantoms when HIFU wasapplied at intensities less than 650 W/cm2. At 650 W/cm2
for 20 s, small bubble fields averaging <4 mm3 are formed.
These areas were most likely boiling clouds generated
from dissolved gases in the phantom gel.
Ablation lesion size as a function of the HIFU treatment
cycle
Varying the ‘off ’ or cool-down time that separated abla-
tive insonation by 2, 4, and 6 s did not affect the volume
of the ablation lesion for a given intensity and duration
of insonation (Figure 7). However, a statistically signifi-
cant dose responsive relationship (ANOVA, p < 0.001)
was observed between the insonation time and the vol-
ume of the resulting ablation lesion (Figure 8). Averaging
all measurements collected at a given insonation time
demonstrated this relationship to be present even at the
lowest acoustic intensity of 140 W/cm2 (PNP = 2 MPa),
although the resulting ablation lesions were small and
appeared inconsistently. On average, these ablation le-
sions measured just 4 mm3 after 20 s of HIFU, despite
the fact that the phantoms contained the highest PFC
concentration (1 × 107 ND per milliliter). This finding
again demonstrated that 140 W/cm2 should be consid-
ered the minimum required intensity to achieve control-
lable ablation with this PSNE. When higher intensities
were applied, the ablation lesions were significantly
larger, even though the PFC concentrations were lower.
Phantoms containing 2.5 × 106 ND per milliliter received
HIFU at an intensity of 390 W/cm2 (PNP = 3 MPa).
The resulting ablation lesions measured 8 mm3 after
5 s and 37 mm3 after 20 s. Applying an intensity of
650 W/cm2 (PNP = 4 MPa) to phantoms containing 5 ×
AB
C 
Figure 7 Ablation lesion size as a function of the separation
time of the HIFU treatment cycle. At intensities of (A) 140,
(B) 390, and (C) 650 W/cm2, no statistically significant differences
were observed between the volumes of the ablation lesions at
separation times of 2, 4, and 6 s for any given insonation time
(n ≥ 4, mean ± S.D.).
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ranging from 19 to 135 mm3 with insonation times from
5 to 20 s.
Minimal ablation occurred in phantoms containing no
PFC agent. The average ablation lesion in response to
the maximum energy delivered during these experiments
[20 s of continuous wave HIFU at 650 W/cm2 (PNP = 4
MPa)] measured 3 mm3, and the appearance of these le-
sions was inconsistent.
Optimizing acoustic parameters for a given PFC
concentration
The results of this study demonstrate that the size of an
ablation lesion produced during PFC-enhanced HIFU
can be predicted in vitro from the acoustic intensity,
the duration of insonation, and the concentration of
the PFC agent. This level of control would theoretic-
ally allow selection of the best acoustic parameters
(intensity and insonation time) to produce an ablation
lesion of desired size in a region of known PFC con-
centration. These relationships can be visualized by a three-
dimensional plot relating acoustic intensity, insonation
time, PFC nanodroplet concentration, and ablation lesion
size (Figure 9). It should be noted that these quanti-
fied relationships apply only to this specific PSNE, al-
though it is reasonable to assume that similar relationships
could be defined for other PSNEs.Figure 8 Ablation lesion size as a function of the duration of
insonation (‘on’ or ablation time). The inset shows the lowest
intensity data in detail. n ≥ 12, mean ± S.D., p < 0.001 for values
along each intensity curve (ANOVA), single asterisk (*) indicates
significance (p < 0.008) from all other insonation times for the given
acoustic intensity (Bonferroni correction to Student's t test).
Lesion Volu
me (mm3) 
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Figure 9 Relationships between acoustic intensity, insonation time, PFC nanodroplet concentration, and ablation lesion size.
This three-dimensional grid demonstrates the best acoustic parameters (intensity and insonation time) to produce an ablation lesion of desired
size in a region containing a known agent concentration for this specific PSNE.
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the ablation lesions within them
Both the volume of the vaporization field (microbubble
cloud) and the volume of the ablation lesion within the
microbubble cloud increased with increasing insonation
times (Figures 6 and 8). The vaporization clouds were
larger than the ablation lesions contained within them.
After 5 s at 650 W/cm2, the vaporization field was four
times larger than its ablation lesion. However, with in-
creasing insonation time, ablation occurred in a larger
portion of the vaporization field. For example, after 20 s
at 650 W/cm2, this ratio was down to 1.75. Similarly, ab-
lation filled more of the microbubble cloud when higher
intensities were used. After 20 s of HIFU at 140 W/cm2,
the vaporization field was about 7.5-fold larger than
the ablation lesion within it, compared to 1.75-fold at
650 W/cm2. These trends probably, at least in part,
reflected the containment of the vaporization field
within the gel boundaries that are present in this ex-
perimental setup. However, the fact that ablation fills
more of the microbubble cloud with higher intensities
and insonation times also suggested that vaporization
and ablation grew outward from the central focal zone
throughout the continuous wave insonation.
Discussion
PFC microbubbles act as cavitation nuclei and lower the
acoustic intensity required to achieve ablation by HIFU.
Lowered energy requirements should improve HIFU
safety and make it a viable option to treat a broader
range of disease sites. Vaporizing liquid PFC droplets in
the target area provides an attractive option for introdu-
cing these microbubbles, given the stability of PFC droplets
in circulation and the fact that they can be manufacturedsmall enough (<300 nm) to extravasate through the leaky
tumor vasculature. Previous testing has confirmed that
phase-shift agents using several different PFC formulations
produce larger ablation lesions with lower HIFU energies
[9,17,20]. However, clinical utility requires control over the
size, shape, and location of the ablation lesion, and this
control can be problematic when PFC agents are present
in the acoustic field [9,11,20,21], particularly if the PSNE
includes a volatile PFC component.
This study explored the use of a PSNE containing
highly volatile DFB (1:1 mix of DFB and DDFP) in a gel
model of HIFU enhancement. Lowering the intensity
needed to achieve vaporization by the addition of a vola-
tile PFC component can minimize HIFU intensity require-
ments. However, since the acoustic pressure that triggers
vaporization is similar to the pressure that drives cavita-
tion, establishing a vaporization field that does not grow
during lower amplitude continuous wave insonation is not
possible. Therefore, these experiments focused on opti-
mizing acoustic parameters (intensity and insonation
time) to achieve controllable HIFU enhancement for a
given concentration of this novel PSNE. Previous testing
has defined the limits of effective acoustic intensity for this
PSNE [9]. Even when PSNE was present, no ablation was
seen at intensities below 140 W/cm2, and ablation in
agent-free gels started to occur above 650 W/cm2. There-
fore, the current study explored the effects of varying
insonation (‘on’) and separation (‘off ’) times of the HIFU
treatment cycle within the intensity range from 140 to
650 W/cm2. It should be noted that this intensity range
corresponds well with the range (157 to 550 W/cm2) iden-
tified by Zhang P. et al. as most appropriate for PFC-
enhanced HIFU [20]. In contrast, current HIFU systems
in use clinically must operate at intensities at or above
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site. This study demonstrated that appropriate acoustic in-
tensities and insonation times can be selected to maintain
control over ablation lesion size, shape, and location even
in the presence of a PSNE containing a volatile PFC com-
ponent. Additionally, since the vaporization field was not
fixed, relatively large ablation lesions that propagated out-
ward from the acoustic focus could be produced. The ab-
lation lesions measured up to 135 mm3 in gels with PSNE,
compared to lesions measuring <4 mm3 in agent-free gels,
when HIFU was applied at 650 W/cm2 for 20 s.
There are interesting similarities and differences between
these findings and the results of other phase-shift studies
looking at HIFU enhancement by PFC nanodroplets and
microdroplets in acrylamide gels. Using a DDFP-based
PSNE without a more volatile component, Zhang P. et al.
were also able to produce ablation lesions larger than
100 mm3. However, the required intensities (around
2,000 W/cm2) were higher [20]. It is suspected that the
differences in ablation response between these two studies
resulted primarily from the presence of volatile DFB in
our PSNE. Testing in solution has demonstrated that
incorporating a lower boiling point PFC during the PSNE
preparation decreases the vaporization threshold of the
PSNE [16]. As a result of this lower threshold, the
vaporization field increased in volume throughout the
continuous wave HIFU treatment cycle in our study
(Figure 6). In contrast, in the presence of DDFP alone,
Zhang P. et al. established a stable vaporization field
using a 30-cycle high-intensity (4,586 W/cm2) pulse and
followed this with 15 s of continuous wave HIFU [20].
Additionally, it should be noted that the frequency of
applied HIFU was also different in these two studies
(1 vs. 3.2 MHz). PFC droplet vaporization is a frequency-
dependent phenomenon, and frequency differences alter
ultrasound wave attenuation, energy deposition, and
microbubble cavitation [29].
Zhang M. et al. studied DDFP microdroplet enhanced
HIFU delivered at a frequency (1.44 MHz) similar to
ours [21]. They too noted increasing ablation lesion vol-
umes with longer insonation times (insonation duration
2 to 5 s). However, at comparable PFC agent concentra-
tions (3 vs. 5 × 105 droplets per milliliter) and insonation
duration (5 s), the ablation responses were quite differ-
ent. Probably reflecting the use of larger PFC droplets
(2 to 8 microns) and a higher intensity (4,000 W/cm2),
Zhang M. et al. produced ablation lesions measuring 600
mm3, compared to 20 mm3 in our study [21].
Finally, again testing a DDFP PSNE in acrylamide gels,
Kawabata et al. applied HIFU using acoustic parameters
(frequency, 1.1 MHz; intensity, 600 W/cm2; insonation
duration, 5 to 20 s) similar to our study and found in-
creasing ablation lesion size with longer insonation [29].
However, lesion size did not increase when HIFU wasapplied at 2.2 MHz. The similarities and differences be-
tween these studies emphasize the fact that the ablation
response during PSNE enhanced HIFU results from a
complex interplay of the applied acoustic parameters as
well as the type and size of the PFC agent. As a result, it
is suspected that changing the ratio of DFB and DDFP
in our PSNE would alter both the vaporization and abla-
tion responses and is a potential area of future study.
The ablation lesions formed in this study were located
in larger vaporization fields (microbubble clouds). The
fact that the vaporization field grows throughout the
entire HIFU treatment cycle when a volatile PSNE is
present distinguishes this study from previous phase-
shift enhancement studies. Continuous vaporization pro-
vides an opportunity to generate larger ablation lesions
but also introduces unique challenges with regard to con-
trolling the ablation response. Anticipating the extent of
vaporization surrounding an ablation site is of practical
importance when positioning adjacent lesions. Separating
insonation by 2, 4, or 6 s did not affect the size of the
vaporization field or the ablation lesion within this
microbubble cloud when adjacent HIFU sites were 8 mm
apart. Decreasing this separation distance could result in
overlapping vaporization fields. Future study will be
needed to assess the impact of overlapping vaporization
fields on tissue heating and the ablation response.
In this gel model, controlled ablation could be achieved
using acoustic parameters that did not result in lesion for-
mation in agent-free regions (frequency = 1 MHz, inten-
sity ≤ 650 W/cm2, insonation time ≤ 20 s). However, the
limitations of this model should be noted. The phantoms
and surrounding gels were acellular and avascular. There-
fore, tissue injury that would result from mechanical
cavitation effects was not captured, and heat sink ef-
fects of blood flow were not considered. Also, changes in
acoustic impedance due to trapped degassed water be-
tween the acrylamide gel cap, the PFC-containing phan-
tom, and the gellan gum mold resulted in echogenic
boundaries, which may have slightly attenuated transmit-
ted energies. Such distinct separations between agent-free
and PFC-containing tissue regions would not be seen
in vivo nor would the uniform distribution of PFC agent
achievable in vitro.
A PSNE concentration in the range of 105 to 107 ND
per milliliter was required for enhanced ablation in this
gel model. Further experimentation will be needed to
determine how these concentrations can be achieved
in vivo. Recent testing has shown that the intravenous
administration of a DDFP-based PSNE (0.5 mL/kg)
resulted in the preferential deposition of nanodroplets in
the vascular periphery of a rabbit tumor [17]. These
agents remained stable for hours and accumulated to a
concentration sufficient to lower the energy required to
reach an ablative temperature by HIFU. The DDFP PSNE
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P. et al. in concentrations similar to those used in our
current study [20]. It is therefore reasonable to assume
that effective tissue concentrations of our DFB-DDFP
PSNE can also be achieved. However, to date, tissue con-
centrations of PFC nanodroplets following the administra-
tion of a PSNE have not been quantified in vivo. Magnetic
resonance of fluorine or gadolinium-tagged agents may
provide a tool to measure PFC tissue concentrations
[20,30]. The development of such a tool may be an im-
portant step on the path toward using PSNEs clinically for
several reasons. First, there is a heterogeneous deposition
of PFC in tumor tissue following the intravenous adminis-
tration of a PSNE [17], quite different from the uniform
distribution used for in vitro studies. Second, as this and
other studies have now demonstrated, controlled ablation
requires selecting appropriate acoustic parameters for a
given PSNE concentration. Therefore, the safe application
of HIFU in a field containing an unequal distribution of
PFC agent may require estimating regional PFC concen-
trations and adjusting the acoustic parameters accord-
ingly. We envision a magnetic resonance-guided focused
ultrasound surgery system that maps the distribution of
PFC tissue levels, selects appropriate acoustic parameters
for the target region and desired lesion size, and monitors
ablation by thermometry.
Conclusions
Research in this and other laboratories has now vali-
dated the use of phase-shift PFC nanoemulsions to en-
hance HIFU by seeding the acoustic target area with
potential cavitation sites. Several methods are available
to synthesize nanodroplets that are stable to circulate
at body temperature and small enough to extravasate
into interstitial tissue spaces. Additionally, appropriate
nanodroplet concentrations and acoustic parameters are
being defined to achieve enhancement (larger ablation le-
sions using shorter treatment cycles and lower acoustic
power) while maintaining control over lesion shape and
location. This in vitro study used a unique PSNE
containing a volatile PFC component and found that
enhanced ablation could be achieved with acoustic in-
tensities low enough to avoid ablation in agent-free
regions. However, control over the ablation response
was problematic, unless specific acoustic parameters were
selected for the available PSNE concentration. These find-
ings support continued experimentation using PSNEs
to enhance HIFU but also emphasize the importance
of exploring tools to quantify PFC tissue concentrations
in vivo to guide acoustic parameter selection.Abbreviations
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